InMed Pharmaceuticals Regains Nasdaq Compliance, Averting Delisting Threat
INM has more than doubled off its 52-week low of $0.575 on light trading volume (0.1× avg).
Summary
InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, receiving notice on June 3, 2026, that its stock traded above $1.00 for 10 consecutive business days. This follows a March 27, 2026, notification of non-compliance and a May 6, 2026, 10-Q filing that cited Nasdaq delisting risks. The stock's recovery above $1.00 coincided with the May 19, 2026, announcement of an all-stock merger with Mentari Therapeutics. Resolving this compliance issue removes an immediate delisting threat, which is a positive for investor confidence and liquidity, especially given the company's ongoing financial challenges and recent merger activity.
At the time of this announcement, INM was trading at $1.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.58 to $5.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.